ID   RAD9A_HUMAN             Reviewed;         391 AA.
AC   Q99638; B2RCZ8; Q6FI29; Q96C41;
DT   07-MAR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   07-APR-2021, entry version 152.
DE   RecName: Full=Cell cycle checkpoint control protein RAD9A;
DE            Short=hRAD9;
DE            EC=3.1.11.2;
DE   AltName: Full=DNA repair exonuclease rad9 homolog A;
GN   Name=RAD9A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8943031; DOI=10.1073/pnas.93.24.13890;
RA   Lieberman H.B., Hopkins K.M., Nass M., Demetrick D., Davey S.;
RT   "A human homolog of the Schizosaccharomyces pombe rad9+ checkpoint control
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13890-13895(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PHE-3; ALA-100; ARG-239 AND
RP   THR-307.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 270-280; 326-329; 373-383 AND 385-390, IDENTIFICATION
RP   BY MASS SPECTROMETRY, PHOSPHORYLATION AT SER-272; SER-277; SER-328;
RP   SER-341; SER-375; SER-380 AND SER-387, AND MUTAGENESIS OF SER-272; SER-277;
RP   SER-328; SER-341; SER-375; SER-380 AND SER-387.
RX   PubMed=12709442; DOI=10.1074/jbc.m301544200;
RA   Roos-Mattjus P., Hopkins K.M., Oestreich A.J., Vroman B.T., Johnson K.L.,
RA   Naylor S., Lieberman H.B., Karnitz L.M.;
RT   "Phosphorylation of human Rad9 is required for genotoxin-activated
RT   checkpoint signaling.";
RL   J. Biol. Chem. 278:24428-24437(2003).
RN   [8]
RP   INTERACTION WITH HUS1 AND RAD1.
RX   PubMed=10359610; DOI=10.1091/mbc.10.6.1985;
RA   St Onge R.P., Udell C.M., Casselman R., Davey S.;
RT   "The human G2 checkpoint control protein hRAD9 is a nuclear phosphoprotein
RT   that forms complexes with hRAD1 and hHUS1.";
RL   Mol. Biol. Cell 10:1985-1995(1999).
RN   [9]
RP   INTERACTION WITH HUS1 AND RAD1.
RX   PubMed=10777662; DOI=10.1006/geno.2000.6142;
RA   Hang H., Lieberman H.B.;
RT   "Physical interaction among human checkpoint control proteins HUS1p, RAD1p,
RT   and RAD9p, and implications for the regulation of cell cycle progression.";
RL   Genomics 65:24-33(2000).
RN   [10]
RP   FUNCTION IN EXONUCLEASE ACTIVITY.
RX   PubMed=10713044; DOI=10.1074/jbc.275.11.7451;
RA   Bessho T., Sancar A.;
RT   "Human DNA damage checkpoint protein hRAD9 is a 3' to 5' exonuclease.";
RL   J. Biol. Chem. 275:7451-7454(2000).
RN   [11]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH HDAC1.
RX   PubMed=10846170; DOI=10.1074/jbc.m000168200;
RA   Cai R.L., Yan-Neale Y., Cueto M.A., Xu H., Cohen D.;
RT   "HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M
RT   checkpoint Rad proteins.";
RL   J. Biol. Chem. 275:27909-27916(2000).
RN   [12]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH RAD17.
RX   PubMed=10884395; DOI=10.1074/jbc.m005782200;
RA   Rauen M., Burtelow M.A., Dufault V.M., Karnitz L.M.;
RT   "The human checkpoint protein hRad17 interacts with the PCNA-like proteins
RT   hRad1, hHus1, and hRad9.";
RL   J. Biol. Chem. 275:29767-29771(2000).
RN   [13]
RP   INTERACTION WITH DNAJC7.
RX   PubMed=11573955; DOI=10.1006/bbrc.2001.5685;
RA   Xiang S.L., Kumano T., Iwasaki S.I., Sun X., Yoshioka K., Yamamoto K.C.;
RT   "The J domain of Tpr2 regulates its interaction with the proapoptotic and
RT   cell-cycle checkpoint protein, Rad9.";
RL   Biochem. Biophys. Res. Commun. 287:932-940(2001).
RN   [14]
RP   INTERACTION WITH ABL1 AND BCL2L1, PHOSPHORYLATION, PHOSPHORYLATION AT
RP   TYR-28, AND MUTAGENESIS OF TYR-28.
RX   PubMed=11971963; DOI=10.1128/mcb.22.10.3292-3300.2002;
RA   Yoshida K., Komatsu K., Wang H.-G., Kufe D.;
RT   "c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 22:3292-3300(2002).
RN   [15]
RP   INTERACTION WITH RAD9B.
RX   PubMed=14500360;
RA   Hopkins K.M., Wang X., Berlin A., Hang H., Thaker H.M., Lieberman H.B.;
RT   "Expression of mammalian paralogues of HRAD9 and Mrad9 checkpoint control
RT   genes in normal and cancerous testicular tissue.";
RL   Cancer Res. 63:5291-5298(2003).
RN   [16]
RP   INTERACTION WITH PRKCD, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12628935; DOI=10.1093/emboj/cdg134;
RA   Yoshida K., Wang H.-G., Miki Y., Kufe D.;
RT   "Protein kinase Cdelta is responsible for constitutive and DNA damage-
RT   induced phosphorylation of Rad9.";
RL   EMBO J. 22:1431-1441(2003).
RN   [17]
RP   ASSOCIATION OF THE 9-1-1 COMPLEX WITH THE RAD17-RFC COMPLEX, AND ELECTRON
RP   MICROSCOPY OF THE 9-1-1 AND RAD17-RFC COMPLEXES BOUND TO DNA.
RX   PubMed=12578958; DOI=10.1073/pnas.0437927100;
RA   Bermudez V.P., Lindsey-Boltz L.A., Cesare A.J., Maniwa Y., Griffith J.D.,
RA   Hurwitz J., Sancar A.;
RT   "Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint
RT   clamp loader hRad17-replication factor C complex in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:1633-1638(2003).
RN   [18]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH POLB.
RX   PubMed=15314187; DOI=10.1093/nar/gkh652;
RA   Toueille M., El-Andaloussi N., Frouin I., Freire R., Funk D., Shevelev I.,
RA   Friedrich-Heineken E., Villani G., Hottiger M.O., Huebscher U.;
RT   "The human Rad9/Rad1/Hus1 damage sensor clamp interacts with DNA polymerase
RT   beta and increases its DNA substrate utilisation efficiency: implications
RT   for DNA repair.";
RL   Nucleic Acids Res. 32:3316-3324(2004).
RN   [19]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH FEN1.
RX   PubMed=15556996; DOI=10.1073/pnas.0407686101;
RA   Wang W., Brandt P., Rossi M.L., Lindsey-Boltz L., Podust V., Fanning E.,
RA   Sancar A., Bambara R.A.;
RT   "The human Rad9-Rad1-Hus1 checkpoint complex stimulates flap endonuclease
RT   1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:16762-16767(2004).
RN   [20]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH LIG1.
RX   PubMed=15871698; DOI=10.1042/bj20050211;
RA   Smirnova E., Toueille M., Markkanen E., Huebscher U.;
RT   "The human checkpoint sensor and alternative DNA clamp Rad9-Rad1-Hus1
RT   modulates the activity of DNA ligase I, a component of the long-patch base
RT   excision repair machinery.";
RL   Biochem. J. 389:13-17(2005).
RN   [21]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH FEN1, AND INTERACTION
RP   WITH FEN1.
RX   PubMed=16216273; DOI=10.1016/j.jmb.2005.09.018;
RA   Friedrich-Heineken E., Toueille M., Taennler B., Buerki C., Ferrari E.,
RA   Hottiger M.O., Huebscher U.;
RT   "The two DNA clamps Rad9/Rad1/Hus1 complex and proliferating cell nuclear
RT   antigen differentially regulate flap endonuclease 1 activity.";
RL   J. Mol. Biol. 353:980-989(2005).
RN   [22]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH RPA1 AND RPA2, AND
RP   INTERACTION WITH RPA1 AND RPA2.
RX   PubMed=15897895; DOI=10.1038/sj.onc.1208674;
RA   Wu X., Shell S.M., Zou Y.;
RT   "Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with
RT   replication protein A in human cells.";
RL   Oncogene 24:4728-4735(2005).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; SER-380 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277; SER-375 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277; SER-375 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [30]
RP   FUNCTION, INTERACTION WITH RHNO1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21659603; DOI=10.1126/science.1203430;
RA   Cotta-Ramusino C., McDonald E.R. III, Hurov K., Sowa M.E., Harper J.W.,
RA   Elledge S.J.;
RT   "A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1
RT   interacting protein required for ATR signaling.";
RL   Science 332:1313-1317(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Component of the 9-1-1 cell-cycle checkpoint response complex
CC       that plays a major role in DNA repair. The 9-1-1 complex is recruited
CC       to DNA lesion upon damage by the RAD17-replication factor C (RFC) clamp
CC       loader complex. Acts then as a sliding clamp platform on DNA for
CC       several proteins involved in long-patch base excision repair (LP-BER).
CC       The 9-1-1 complex stimulates DNA polymerase beta (POLB) activity by
CC       increasing its affinity for the 3'-OH end of the primer-template and
CC       stabilizes POLB to those sites where LP-BER proceeds; endonuclease FEN1
CC       cleavage activity on substrates with double, nick, or gap flaps of
CC       distinct sequences and lengths; and DNA ligase I (LIG1) on long-patch
CC       base excision repair substrates. The 9-1-1 complex is necessary for the
CC       recruitment of RHNO1 to sites of double-stranded breaks (DSB) occurring
CC       during the S phase. RAD9A possesses 3'->5' double stranded DNA
CC       exonuclease activity. Its phosphorylation by PRKCD may be required for
CC       the formation of the 9-1-1 complex. {ECO:0000269|PubMed:10713044,
CC       ECO:0000269|PubMed:21659603}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Exonucleolytic cleavage in the 3'- to 5'-direction to yield
CC         nucleoside 5'-phosphates.; EC=3.1.11.2;
CC   -!- SUBUNIT: Component of the toroidal 9-1-1 (RAD9-RAD1-HUS1) complex,
CC       composed of RAD9A, RAD1 and HUS1. The 9-1-1 complex associates with
CC       LIG1, POLB, FEN1, RAD17, HDAC1, RPA1 and RPA2. The 9-1-1 complex
CC       associates with the RAD17-RFC complex. RAD9A interacts with BCL2L1,
CC       FEN1, PRKCD, RAD9B, HUS1, RAD1, ABL1, RPA1, ATAD5 and RPA2. Interacts
CC       with DNAJC7 and RHNO1. {ECO:0000269|PubMed:10359610,
CC       ECO:0000269|PubMed:10777662, ECO:0000269|PubMed:10846170,
CC       ECO:0000269|PubMed:10884395, ECO:0000269|PubMed:11573955,
CC       ECO:0000269|PubMed:11971963, ECO:0000269|PubMed:12628935,
CC       ECO:0000269|PubMed:14500360, ECO:0000269|PubMed:15314187,
CC       ECO:0000269|PubMed:15556996, ECO:0000269|PubMed:15871698,
CC       ECO:0000269|PubMed:15897895, ECO:0000269|PubMed:16216273,
CC       ECO:0000269|PubMed:21659603}.
CC   -!- INTERACTION:
CC       Q99638; O60921: HUS1; NbExp=13; IntAct=EBI-2606224, EBI-1056174;
CC       Q99638; O60671: RAD1; NbExp=2; IntAct=EBI-2606224, EBI-721835;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12628935}.
CC   -!- PTM: Constitutively phosphorylated on serine and threonine amino acids
CC       in absence of DNA damage. Hyperphosphorylated by PRKCD and ABL1 upon
CC       DNA damage. Its phosphorylation by PRKCD may be required for the
CC       formation of the 9-1-1 complex. {ECO:0000269|PubMed:11971963,
CC       ECO:0000269|PubMed:12628935, ECO:0000269|PubMed:12709442}.
CC   -!- SIMILARITY: Belongs to the rad9 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rad9a/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RAD9AID42031ch11q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U53174; AAB39928.1; -; mRNA.
DR   EMBL; CR536508; CAG38746.1; -; mRNA.
DR   EMBL; AY766122; AAU89725.1; -; Genomic_DNA.
DR   EMBL; AK315348; BAG37745.1; -; mRNA.
DR   EMBL; CH471076; EAW74605.1; -; Genomic_DNA.
DR   EMBL; BC014848; AAH14848.1; -; mRNA.
DR   CCDS; CCDS8159.1; -.
DR   RefSeq; NP_001230153.1; NM_001243224.1.
DR   RefSeq; NP_004575.1; NM_004584.2.
DR   PDB; 3A1J; X-ray; 2.50 A; A=1-266.
DR   PDB; 3G65; X-ray; 2.90 A; A=1-270.
DR   PDB; 3GGR; X-ray; 3.20 A; A=1-270.
DR   PDB; 6HM5; X-ray; 2.33 A; B=380-390.
DR   PDB; 6J8Y; X-ray; 2.40 A; A=1-270.
DR   PDBsum; 3A1J; -.
DR   PDBsum; 3G65; -.
DR   PDBsum; 3GGR; -.
DR   PDBsum; 6HM5; -.
DR   PDBsum; 6J8Y; -.
DR   SMR; Q99638; -.
DR   BioGRID; 111820; 54.
DR   ComplexPortal; CPX-1829; Checkpoint clamp complex.
DR   CORUM; Q99638; -.
DR   DIP; DIP-24255N; -.
DR   DIP; DIP-40930N; -.
DR   IntAct; Q99638; 10.
DR   MINT; Q99638; -.
DR   STRING; 9606.ENSP00000311360; -.
DR   iPTMnet; Q99638; -.
DR   PhosphoSitePlus; Q99638; -.
DR   BioMuta; RAD9A; -.
DR   DMDM; 74717382; -.
DR   EPD; Q99638; -.
DR   jPOST; Q99638; -.
DR   MassIVE; Q99638; -.
DR   MaxQB; Q99638; -.
DR   PaxDb; Q99638; -.
DR   PeptideAtlas; Q99638; -.
DR   PRIDE; Q99638; -.
DR   ProteomicsDB; 78371; -.
DR   Antibodypedia; 1880; 1131 antibodies.
DR   CPTC; Q99638; 1 antibody.
DR   Ensembl; ENST00000307980; ENSP00000311360; ENSG00000172613.
DR   GeneID; 5883; -.
DR   KEGG; hsa:5883; -.
DR   UCSC; uc001okr.4; human.
DR   CTD; 5883; -.
DR   DisGeNET; 5883; -.
DR   GeneCards; RAD9A; -.
DR   HGNC; HGNC:9827; RAD9A.
DR   HPA; ENSG00000172613; Low tissue specificity.
DR   MIM; 603761; gene.
DR   neXtProt; NX_Q99638; -.
DR   OpenTargets; ENSG00000172613; -.
DR   PharmGKB; PA294; -.
DR   VEuPathDB; HostDB:ENSG00000172613.7; -.
DR   eggNOG; KOG2810; Eukaryota.
DR   GeneTree; ENSGT00390000005767; -.
DR   InParanoid; Q99638; -.
DR   OMA; DERMWVR; -.
DR   OrthoDB; 1176140at2759; -.
DR   PhylomeDB; Q99638; -.
DR   TreeFam; TF101212; -.
DR   PathwayCommons; Q99638; -.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   SignaLink; Q99638; -.
DR   SIGNOR; Q99638; -.
DR   BioGRID-ORCS; 5883; 549 hits in 1003 CRISPR screens.
DR   ChiTaRS; RAD9A; human.
DR   EvolutionaryTrace; Q99638; -.
DR   GeneWiki; RAD9A; -.
DR   GenomeRNAi; 5883; -.
DR   Pharos; Q99638; Tbio.
DR   PRO; PR:Q99638; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q99638; protein.
DR   Bgee; ENSG00000172613; Expressed in right uterine tube and 183 other tissues.
DR   ExpressionAtlas; Q99638; baseline and differential.
DR   Genevisible; Q99638; HS.
DR   GO; GO:0030896; C:checkpoint clamp complex; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0008853; F:exodeoxyribonuclease III activity; IEA:UniProtKB-EC.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0000077; P:DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0000076; P:DNA replication checkpoint; IBA:GO_Central.
DR   GO; GO:0031573; P:intra-S DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   InterPro; IPR026584; Rad9.
DR   InterPro; IPR007268; Rad9/Ddc1.
DR   PANTHER; PTHR15237; PTHR15237; 1.
DR   Pfam; PF04139; Rad9; 1.
DR   PIRSF; PIRSF009303; Cell_cycle_RAD9; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; DNA damage; Exonuclease;
KW   Hydrolase; Nuclease; Nucleus; Phosphoprotein; Reference proteome.
FT   CHAIN           1..391
FT                   /note="Cell cycle checkpoint control protein RAD9A"
FT                   /id="PRO_0000225000"
FT   REGION          51..91
FT                   /note="Possesses 3'-5' exonuclease activity"
FT   REGION          266..391
FT                   /note="Sufficient for interaction with ABL1"
FT                   /evidence="ECO:0000269|PubMed:11971963"
FT   MOD_RES         28
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11971963"
FT   MOD_RES         272
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         341
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442,
FT                   ECO:0007744|PubMed:17081983"
FT   MOD_RES         387
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12709442,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   VARIANT         3
FT                   /note="C -> F (in dbSNP:rs11575913)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025410"
FT   VARIANT         71
FT                   /note="L -> Q (in dbSNP:rs2422490)"
FT                   /id="VAR_051724"
FT   VARIANT         100
FT                   /note="S -> A (in dbSNP:rs2066492)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025411"
FT   VARIANT         239
FT                   /note="H -> R (in dbSNP:rs17880039)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025412"
FT   VARIANT         307
FT                   /note="M -> T (in dbSNP:rs17882466)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025413"
FT   MUTAGEN         28
FT                   /note="Y->F: Abolishes phosphorylation by ABL1."
FT                   /evidence="ECO:0000269|PubMed:11971963"
FT   MUTAGEN         272
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-277; A-328; A-341; A-375; A-380 and A-387."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MUTAGEN         277
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-272; A-328; A-341; A-375; A-380 and A-387."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MUTAGEN         328
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-272; A-277; A-341; A-375; A-380 and A-387."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MUTAGEN         341
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-272; A-277; A-328; A-375; A-380 and A-387."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MUTAGEN         375
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-272; A-277; A-328; A-341; A-380 and A-387."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MUTAGEN         380
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-272; A-277; A-328; A-341; A-375 and A-387."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   MUTAGEN         387
FT                   /note="S->A: Complete loss of phosphorylation and no loss
FT                   of interaction with the 9-1-1 complex; when associated with
FT                   A-272; A-277; A-328; A-341; A-375 and A-380."
FT                   /evidence="ECO:0000269|PubMed:12709442"
FT   CONFLICT        12
FT                   /note="V -> A (in Ref. 2; CAG38746)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        130
FT                   /note="E -> A (in Ref. 6; AAH14848)"
FT                   /evidence="ECO:0000305"
FT   STRAND          2..6
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           9..20
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   TURN            21..23
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          25..32
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          35..41
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          43..45
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          47..53
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           55..57
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          58..62
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          66..68
FT                   /evidence="ECO:0007744|PDB:3A1J"
FT   STRAND          73..76
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           77..83
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           87..92
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          94..100
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          103..106
FT                   /evidence="ECO:0007744|PDB:3GGR"
FT   STRAND          107..114
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           115..117
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          119..125
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           138..140
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          142..148
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           149..156
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          165..171
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   TURN            172..174
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          175..180
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          187..189
FT                   /evidence="ECO:0007744|PDB:3GGR"
FT   STRAND          194..199
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           201..203
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          205..208
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          214..218
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   HELIX           219..230
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   TURN            231..233
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          235..240
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          241..245
FT                   /evidence="ECO:0007744|PDB:3GGR"
FT   STRAND          247..252
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          254..262
FT                   /evidence="ECO:0007744|PDB:6J8Y"
FT   STRAND          267..269
FT                   /evidence="ECO:0007744|PDB:3G65"
FT   STRAND          382..384
FT                   /evidence="ECO:0007744|PDB:6HM5"
SQ   SEQUENCE   391 AA;  42547 MW;  4D4D6D4C6E1057D3 CRC64;
     MKCLVTGGNV KVLGKAVHSL SRIGDELYLE PLEDGLSLRT VNSSRSAYAC FLFAPLFFQQ
     YQAATPGQDL LRCKILMKSF LSVFRSLAML EKTVEKCCIS LNGRSSRLVV QLHCKFGVRK
     THNLSFQDCE SLQAVFDPAS CPHMLRAPAR VLGEAVLPFS PALAEVTLGI GRGRRVILRS
     YHEEEADSTA KAMVTEMCLG EEDFQQLQAQ EGVAITFCLK EFRGLLSFAE SANLNLSIHF
     DAPGRPAIFT IKDSLLDGHF VLATLSDTDS HSQDLGSPER HQPVPQLQAH STPHPDDFAN
     DDIDSYMIAM ETTIGNEGSR VLPSISLSPG PQPPKSPGPH SEEEDEAEPS TVPGTPPPKK
     FRSLFFGSIL APVRSPQGPS PVLAEDSEGE G
//
